CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 

Royalty Pharma Plc's Total Debt to Equity

RPRX's quarterly Total Debt to Equity and Total Debt, Equity growth


Despite a net increase in borrowings by 0.07%, Royalty Pharma Plc managed to enhance Total Debt to Equity in the forth quarter 2023 to 0.61, falling below the company's typical Total Debt to Equity.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 8 other companies have achieved lower Total Debt to Equity than Royalty Pharma Plc in the IV Quarter 2023. While Total Debt to Equity total ranking has improved so far in the forth quarter 2023 to 339, from total ranking in the third quarter 2023 at 1600 .

Explain Debt to Equity Ratio?
What is the structure of RPRX´s Total Debt?
How valuable is the RPRX´s Equity?


RPRX Total Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 5.87 % -7.98 % -5.71 % -3.15 % -7.06 %
Y / Y Total Debt Change -13.79 % -13.78 % 0.28 % 0.29 % 0.29 %
Total Debt to Equity MRQ 0.61 0.64 0.73 0.73 0.75
RPRX's Total Ranking # 339 # 1600 # 995 # 1844 # 264
Seq. Equity Change 5.21 % -2.33 % -0.08 % 3.11 % -8.55 %
Seq. Total Debt Change 0.07 % -13.97 % 0.07 % 0.07 % 0.07 %



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 31
Overall Market # 339


Total Debt to Equity Statistics
High Average Low
0.75 0.66 0.56
(Dec 31 2022)   (Jun 30 2021)




Financial Statements
Royalty Pharma Plc's Equity $ 10,084 Millions Visit RPRX's Balance sheet
Royalty Pharma Plc's Total Debt $ 6,135 Millions Visit RPRX's Balance sheet
Source of RPRX's Sales Visit RPRX's Sales by Geography


Cumulative Royalty Pharma Plc's Total Debt to Equity

RPRX's Total Debt to Equity for the trailling 12 Months

RPRX Total Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth 5.87 % -7.98 % -5.71 % -3.15 % -7.06 %
Y / Y Total Debt TTM Growth -13.79 % -13.78 % 0.28 % 0.29 % 0.29 %
Total Debt to Equity TTM 0.67 0.71 0.72 0.71 0.7
Total Ranking TTM # 18 # 1738 # 1959 # 102 # 21
Seq. Equity TTM Growth 5.21 % -2.33 % -0.08 % 3.11 % -8.55 %
Seq. Total Debt TTM Growth 0.07 % -13.97 % 0.07 % 0.07 % 0.07 %


On the trailing twelve months basis Despite of the net new borrowings of 0.07% during the twelve months period ending in IV Quarter 2023 Royalty Pharma Plc has managed to decrease Total Debt to Equity in the IV Quarter 2023 to 0.67, above the RPRX's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 2, during the past 12 months, other companies have achieved lower Total Debt to Equity than Royalty Pharma Plc. While Total Debt to Equity total ranking has improved so far to 18, from total ranking in previous 12 month period at 1738.

Explain Debt to Equity Ratio?
What is the structure of RPRX´s Total Debt?
How valuable is the RPRX´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 5
Within the Market # 18


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.72 0.65 0.58
(Jun 30 2023)   (Jun 30 2021)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2023 MRQ Total DebtDec 31 2023 MRQ Equity
Eyenovia inc   1.59 $ 14.287  Millions$ 8.999  Millions
Jazz Pharmaceuticals Plc  1.53 $ 5,712.942  Millions$ 3,736.997  Millions
G1 Therapeutics Inc   1.46 $ 51.557  Millions$ 35.386  Millions
Xoma Corporation  1.40 $ 124.061  Millions$ 88.721  Millions
Alimera Sciences Inc   1.40 $ 64.489  Millions$ 46.170  Millions
Biovie Inc   1.36 $ 10.195  Millions$ 7.491  Millions
Catalent Inc   1.36 $ 5,005.000  Millions$ 3,687.000  Millions
Bristol myers Squibb Company  1.35 $ 39,772.000  Millions$ 29,485.000  Millions
Emergent Biosolutions Inc   1.32 $ 860.200  Millions$ 649.300  Millions
Zoetis Inc   1.32 $ 6,567.000  Millions$ 4,991.000  Millions
Soligenix inc   1.29 $ 3.261  Millions$ 2.522  Millions
Summit Therapeutics Inc   1.29 $ 100.000  Millions$ 77.692  Millions
Clene Inc   1.23 $ 16.521  Millions$ 13.390  Millions
Lexicon Pharmaceuticals Inc   1.07 $ 99.508  Millions$ 93.110  Millions
Merck and Co Inc   0.93 $ 35,055.000  Millions$ 37,635.000  Millions
Elanco Animal Health Inc  0.93 $ 5,774.000  Millions$ 6,223.000  Millions
Viatris Inc   0.89 $ 18,131.500  Millions$ 20,467.400  Millions
Perrigo Company Plc  0.85 $ 4,073.400  Millions$ 4,767.900  Millions
Ocular Therapeutix Inc   0.82 $ 74.925  Millions$ 91.131  Millions
Biofrontera Inc   0.81 $ 3.904  Millions$ 4.793  Millions
Pfizer Inc  0.81 $ 71,888.000  Millions$ 89,288.000  Millions
Cryoport inc   0.78 $ 380.037  Millions$ 489.023  Millions
Prestige Consumer Healthcare Inc   0.75 $ 1,199.340  Millions$ 1,600.577  Millions
Lucy Scientific Discovery Inc   0.75 $ 0.060  Millions$ 0.081  Millions
Vaxxinity Inc   0.74 $ 9.933  Millions$ 13.409  Millions
Verastem inc   0.70 $ 40.086  Millions$ 57.374  Millions
Mersana Therapeutics Inc   0.68 $ 25.231  Millions$ 36.904  Millions
Ani Pharmaceuticals Inc  0.66 $ 285.669  Millions$ 432.749  Millions
Royalty Pharma Plc  0.61 $ 6,135.285  Millions$ 10,084.289  Millions
Aytu Biopharma Inc   0.49 $ 16.043  Millions$ 32.853  Millions

Date modified: 2024-02-15T15:42:59+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com